NEUP - Neuphoria PEG Multiple

Corporate company logo of Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Inc. (NEUP) plans to generate revenue by bringing therapies for cognitive and depressive pathologies to market. The PEG ratio clearly demonstrates the dynamics of this process, with the value of 0.00 serving as the current metric. Management is aggressively pushing clinical trials and seeking partners. The asset is in the final stage of development; therefore, quotes depend on the outcome of the trials, ignoring macroeconomic factors.

Neuphoria Therapeutics, Inc. (NEUP) - PEG Multiple from 12/25/2024 to 11/16/2026

Metric breakdowns and analytics for Neuphoria Therapeutics, Inc. (NEUP)

- current quotes and average value forecast:
General company analysis:NEUP, Neuphoria
Mass-produced product of Neuphoria Therapeutics

For the high-volatility biotech sector, the PEG ratio serves as a tool for benchmarking market value against earnings growth. The ratio of the P/E multiple to earnings growth rates, reflected in the PEG indicator's fluctuations, determines the degree of an asset's undervaluation. A value below one signals potential price appreciation. However, for Neuphoria Therapeutics Inc. (NEUP), the binary risks associated with a narrow CNS drug portfolio render this indicator secondary. Fundamental stability here depends on the outcome of clinical trials.

Competing companies

Growth-Adjusted Market Cap to Net Income Biogen Idec|Neurocrine Corp - Price/Earnings to Growth Multiple|regencellbioscience.com (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Growth-Adjusted P/E Ratio|Xenon Pharmaceuticals (XENE) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus|Price to Earnings Adjusted for Growth Rate catalystpharma.com CPRX|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics Inc.)|HRMY - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Biohaven Ltd. BHVN|AMLX (Amylyx) - Market Cap to Earnings and Growth Ratio|Trevi Therapeutics Inc - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Precision Medicines)|AVXL: PEG Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio prothena.com|Price/Earnings to Growth Multiple Alector (ALEC)|Price/Earnings to Growth Multiple ANNX (annexonbio.com)|OMER - Price to Earnings Adjusted for Growth Rate|PEG Multiple NGNE (Neurogene Inc)|PEG Multiple AC Immune S.A. ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX (Scilex Holding Company) - Price/Earnings to Growth Multiple|TVGN (Tevogen Bio Holdings) - Price/Earnings to Growth Ratio|ACOG (Alpha Cognition Corp) - PEG Multiple|Cognition Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|PEG Multiple IKT|SAVA (Cassava) - Growth-Adjusted Payback Ratio|Assertio Holdings, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio COYA|VistaGen Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Ovid Therapeutics OVID|ABOS: PEG Multiple|CervoMed Corporation (CRVO) - PEG Multiple|Price/Earnings to Growth Ratio Alterity Therapeutics Limited|Price/Earnings to Growth Ratio CLNN|PEG Multiple PEPG|JUNS (Jupiter Neurosciences) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Relmada Corp RLMD|PEG Multiple Annovis Bio Corporation ANVS|gracetx.com - PEG Multiple|Firefly Neuroscience, Inc (AIFF) - Price/Earnings to Growth Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Ratio|NeuroSense Therapeutics, Ltd. - Growth-Adjusted Payback Ratio|RVPH (Reviva Pharmaceuticals Holdings) - PEG Multiple|MetaVia Inc (MTVA) - Growth-Adjusted Market Cap to Net Income|PEG Multiple NRXS|Growth-Adjusted Market Cap to Net Income Helius Medical Technologies Inc.|Price/Earnings to Growth Ratio passagebio.com PASG|PEG Multiple Minerva Neurosciences Inc NERV|ATHA: Price/Earnings to Growth Multiple|ADXN (Addex Therapeutics, Ltd.) - Growth-Adjusted P/E Ratio|Alzamend Neuro Inc. (ALZN) - Price/Earnings to Growth Ratio|Cyclerion - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio protagenic.com|Pasithea Therapeutics - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple